Indeed, significant changes in the other outcome variables were also noted already at week 4 including reduction of TB scores, significantly elevated concentration of plasma 25(OH)D3, LL-37 mRNA, LL-37 peptide in PBMC and lymphocytes in the different intervention groups compared to the placebo. Here, CAMP is linked to tuberculosis.